Form 4 for VTR Ventas
Accepted 2025-11-03 00:00:00 ET · period of report 2025-10-30 · accession 0001215188-25-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-03 | 2025-10-30+ | VTR | CAFARO DEBRA A | COB, CEO, Dir | M - OptEx | $63.98 | +337.9K | 1.18M | +40% | +$21.62M |
| DM | 2025-11-03 | 2025-10-30+ | VTR | CAFARO DEBRA A | COB, CEO, Dir | S - Sale+OE | $74.22 | -337.9K | 1.15M | -23% | -$25.08M |
| DM | 2025-11-03 | 2025-10-30+ | VTR | CAFARO DEBRA A | COB, CEO, Dir | M - OptEx | $0.00 | -337.9K | 113.5K | -75% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-30 | M | A | 41,288 | $63.24 | 1,186,983 | D | — | — | (F5) The transaction involved the exercise of fully vested options scheduled to expire in the next 13 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. |
| 2 | Common | Common Stock | 2025-10-30 | S | D | 41,288 | $73.64 | 1,145,695 | D | — | — | (F5) The transaction involved the exercise of fully vested options scheduled to expire in the next 13 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. (F6) The price reported is a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $72.05 to $74.71, inclusive. The Reporting Person undertakes to provide Issuer, any security holder of Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2025-10-30 | M | A | 224,360 | $62.22 | 1,370,055 | D | — | — | (F7) The transaction involved the exercise of fully vested options scheduled to expire in the next 15 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. |
| 4 | Common | Common Stock | 2025-10-30 | S | D | 224,360 | $74.34 | 1,145,695 | D | — | — | (F7) The transaction involved the exercise of fully vested options scheduled to expire in the next 15 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. (F8) The price reported is a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $74.00 to $74.68, inclusive. The Reporting Person undertakes to provide Issuer, any security holder of Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2025-11-03 | M | A | 10,322 | $73.71 | 1,156,017 | D | — | — | (F3) The transaction involved the exercise of fully vested options scheduled to expire in the next 10 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. |
| 6 | Common | Common Stock | 2025-11-03 | S | D | 10,322 | $73.98 | 1,145,695 | D | — | — | (F3) The transaction involved the exercise of fully vested options scheduled to expire in the next 10 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. (F9) The price reported is a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $73.86 to $74.1829, inclusive. The Reporting Person undertakes to provide Issuer, any security holder of Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Common | Common Stock | 2025-11-03 | M | A | 10,322 | $63.24 | 1,156,017 | D | — | — | (F5) The transaction involved the exercise of fully vested options scheduled to expire in the next 13 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. |
| 8 | Common | Common Stock | 2025-11-03 | S | D | 10,322 | $73.74 | 1,145,695 | D | — | — | (F5) The transaction involved the exercise of fully vested options scheduled to expire in the next 13 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. (F10) The price reported is a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $72.86 to $74.17, inclusive. The Reporting Person undertakes to provide Issuer, any security holder of Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 9 | Common | Common Stock | 2025-10-30 | M | A | 20,644 | $65.45 | 1,166,339 | D | — | — | (F1) The transaction involved the exercise of fully vested options scheduled to expire in the next 7 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. |
| 10 | Common | Common Stock | 2025-10-30 | S | D | 20,644 | $74.34 | 1,145,695 | D | — | — | (F1) The transaction involved the exercise of fully vested options scheduled to expire in the next 7 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. (F2) The price reported is a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $74.00 to $74.66, inclusive. The Reporting Person undertakes to provide Issuer, any security holder of Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 11 | Common | Common Stock | 2025-10-30 | M | A | 30,966 | $73.71 | 1,176,661 | D | — | — | (F3) The transaction involved the exercise of fully vested options scheduled to expire in the next 10 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. |
| 12 | Common | Common Stock | 2025-10-30 | S | D | 30,966 | $74.32 | 1,145,695 | D | — | — | (F3) The transaction involved the exercise of fully vested options scheduled to expire in the next 10 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. (F4) The price reported is a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $73.87 to $74.68, inclusive. The Reporting Person undertakes to provide Issuer, any security holder of Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 13 | Derivative | Stock Option (Right to Buy) | 2025-10-30 | M | D | 20,644 | $0.00 | 430,806 | D | $65.45 · 2016-05-04 to 2026-05-04 | 20,644 Common Stock | (F1) The transaction involved the exercise of fully vested options scheduled to expire in the next 7 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. (F12) Represents total number of unexercised options to purchase shares of Issuer's Common Stock held by the Reporting Person. (F11) Fully vested. |
| 14 | Derivative | Stock Option (Right to Buy) | 2025-10-30 | M | D | 30,966 | $0.00 | 399,840 | D | $73.71 · 2016-08-03 to 2026-08-03 | 30,966 Common Stock | (F3) The transaction involved the exercise of fully vested options scheduled to expire in the next 10 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. (F12) Represents total number of unexercised options to purchase shares of Issuer's Common Stock held by the Reporting Person. (F11) Fully vested. |
| 15 | Derivative | Stock Option (Right to Buy) | 2025-10-30 | M | D | 41,288 | $0.00 | 358,552 | D | $63.24 · 2016-11-02 to 2026-11-02 | 41,288 Common Stock | (F5) The transaction involved the exercise of fully vested options scheduled to expire in the next 13 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. (F12) Represents total number of unexercised options to purchase shares of Issuer's Common Stock held by the Reporting Person. (F11) Fully vested. |
| 16 | Derivative | Stock Option (Right to Buy) | 2025-10-30 | M | D | 224,360 | $0.00 | 134,192 | D | $62.22 · 2017-01-18 to 2027-01-18 | 224,360 Common Stock | (F7) The transaction involved the exercise of fully vested options scheduled to expire in the next 15 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. (F12) Represents total number of unexercised options to purchase shares of Issuer's Common Stock held by the Reporting Person. (F11) Fully vested. |
| 17 | Derivative | Stock Option (Right to Buy) | 2025-11-03 | M | D | 10,322 | $0.00 | 123,870 | D | $73.71 · 2016-08-03 to 2026-08-03 | 10,322 Common Stock | (F3) The transaction involved the exercise of fully vested options scheduled to expire in the next 10 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. (F12) Represents total number of unexercised options to purchase shares of Issuer's Common Stock held by the Reporting Person. (F11) Fully vested. |
| 18 | Derivative | Stock Option (Right to Buy) | 2025-11-03 | M | D | 10,322 | $0.00 | 113,548 | D | $63.24 · 2016-11-02 to 2026-11-02 | 10,322 Common Stock | (F5) The transaction involved the exercise of fully vested options scheduled to expire in the next 13 months and the sale of the underlying shares net of the exercise price and taxes, all pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024. (F12) Represents total number of unexercised options to purchase shares of Issuer's Common Stock held by the Reporting Person. (F11) Fully vested. |